Ionis Pharmaceuticals Inc (IONS) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 444.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 62,572 shares of the company’s stock after buying an additional 80,763 shares during the period. JPMorgan Chase & Co. owned about 0.05% of Ionis Pharmaceuticals worth $3,292,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Hanseatic Management Services Inc. boosted its holdings in Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after buying an additional 41 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after buying an additional 311 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Ionis Pharmaceuticals by 0.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 100,250 shares of the company’s stock worth $5,100,000 after buying an additional 387 shares during the last quarter. Prudential Financial Inc. boosted its holdings in Ionis Pharmaceuticals by 4.9% in the 2nd quarter. Prudential Financial Inc. now owns 8,641 shares of the company’s stock worth $440,000 after buying an additional 400 shares during the last quarter. Finally, First Allied Advisory Services Inc. boosted its holdings in Ionis Pharmaceuticals by 9.9% in the 2nd quarter. First Allied Advisory Services Inc. now owns 5,463 shares of the company’s stock worth $279,000 after buying an additional 494 shares during the last quarter. Institutional investors own 91.40% of the company’s stock.

Several research firms recently issued reports on IONS. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. BMO Capital Markets restated an “outperform” rating and set a $69.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd. Barclays lowered their target price on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a report on Thursday, September 21st. BidaskClub cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 22nd. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company’s stock. Ionis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $50.31.

Ionis Pharmaceuticals Inc (IONS) opened at $49.48 on Friday. The firm has a market capitalization of $6,242.27, a P/E ratio of 333.47 and a beta of 2.86. Ionis Pharmaceuticals Inc has a twelve month low of $37.26 and a twelve month high of $65.51. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50.

In other news, SVP Richard S. Geary sold 8,268 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of $60.00, for a total transaction of $496,080.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Stanley T. Crooke sold 16,500 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of $59.46, for a total transaction of $981,090.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 94,549 shares of company stock worth $5,538,170. Corporate insiders own 2.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Ionis Pharmaceuticals Inc (IONS) Shares Bought by JPMorgan Chase & Co.” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.com-unik.info/2018/01/05/ionis-pharmaceuticals-inc-ions-shares-bought-by-jpmorgan-chase-co.html.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

What are top analysts saying about Ionis Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ionis Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit